Is Adicet Bio, Inc. (ACET) a Buy, Sell, or Hold?
Adicet Bio, Inc.
NASDAQ:ACET
$8.83 USD
$0.28 (3.27%)
- Volume
- 119.94K
- Average Volume
- 108.61K
- Market Capitalization
- $82.54M
- P/E Ratio
- -0.59
- Dividend Yield
- 0.00%
- Price Target
- $432.00
- Year High
- $17.44
- Year Low
- $6.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.65
| Source | Headline |
|---|---|
|
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year. zacks.com - 2026-07-01 10:41:17 |
|
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company's focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune disease and oncology. marketbeat.com - 2026-06-04 14:05:29 |
|
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year. zacks.com - 2026-05-28 10:40:44 |
|
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2026-05-25 10:56:13 |
|
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2026. “Adicet is approaching a key inflection point as we prepare to report Phase 1 data for prula-cel in mid-year 2026, including data from at least 20 LN and SLE patients with a minimum. businesswire.com - 2026-05-13 16:01:00 |
